tradingkey.logo

Nautilus Biotechnology Inc

NAUT
查看详细走势图
1.980USD
+0.040+2.06%
收盘 12/22, 16:00美东报价延迟15分钟
250.08M总市值
亏损市盈率 TTM

Nautilus Biotechnology Inc

1.980
+0.040+2.06%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+2.06%

5天

+4.21%

1月

-11.61%

6月

+177.04%

今年开始到现在

+17.86%

1年

+12.50%

查看详细走势图

TradingKey Nautilus Biotechnology Inc股票评分

单位: USD 更新时间: 2025-10-27

操作建议

当前估值合理,机构持股占比非常高,近一月多位分析师给出公司评级为强力买入。最高目标价max_target_price。目前股价在压力位和支撑位之间,可以做区间波段操作。

Nautilus Biotechnology Inc评分

相关信息

行业排名
210 / 501
全市场排名
370 / 4682
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 2 位分析师
强力买入
评级
2.500
目标均价
+23.15%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Nautilus Biotechnology Inc亮点

亮点风险
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
利润高增长
公司净利润处于行业前列,最新年度总收入0.00美元
估值高估
公司最新PE估值-2.59,处于3年历史高位
机构减仓
最新机构持股57.12M股,环比减少6.05%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值619.91K
活跃度降低
近期活跃度降低,过去20天平均换手率0.45

Nautilus Biotechnology Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Nautilus Biotechnology Inc简介

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
公司代码NAUT
公司Nautilus Biotechnology Inc
CEOPatel (Sujal)
网址https://www.nautilus.bio/

常见问题

Nautilus Biotechnology Inc(NAUT)的当前股价是多少?

Nautilus Biotechnology Inc(NAUT)的当前股价是 1.980。

Nautilus Biotechnology Inc的股票代码是什么?

Nautilus Biotechnology Inc的股票代码是NAUT。

Nautilus Biotechnology Inc股票的52周最高点是多少?

Nautilus Biotechnology Inc股票的52周最高点是2.540。

Nautilus Biotechnology Inc股票的52周最低点是多少?

Nautilus Biotechnology Inc股票的52周最低点是0.620。

Nautilus Biotechnology Inc的市值是多少?

Nautilus Biotechnology Inc的市值是250.08M。

Nautilus Biotechnology Inc的净利润是多少?

Nautilus Biotechnology Inc的净利润为-70.78M。

现在Nautilus Biotechnology Inc(NAUT)的股票是买入、持有还是卖出?

根据分析师评级,Nautilus Biotechnology Inc(NAUT)的总体评级为--,目标价格为2.500。

Nautilus Biotechnology Inc(NAUT)股票的每股收益(EPS TTM)是多少

Nautilus Biotechnology Inc(NAUT)股票的每股收益(EPS TTM)是-0.498。
KeyAI